The U.S. Food and Drug Administration (FDA) has granted traditional approval to Braftovi (encorafenib) for adult patients ...
Traditional approval of encorafenib plus cetuximab and fluorouracil-based chemotherapy for patients with BRAF-mutated ...
The FDA has approved the first combination, targeted regimen for previously untreated BRAF V600E mutation-positive metastatic colorectal cancer.Encorafenib (Braftovi, Pfizer) plus cetuximab (Erbitux, ...
SOUTH SAN FRANCISCO, Calif.-- (BUSINESS WIRE)--February 24, 2026-- ...
Pfizer Inc. PFE shares are trending on Wednesday following the U.S. Food and Drug Administration’s (FDA) full approval of the BRAFTOVI combination regimen for treating metastatic colorectal cancer.
Preliminary results of fruquintinib in combination with FOLFIRI as second-line treatment for RAS-mutant metastatic colorectal cancer: A prospective, single-center phase 2 study. Efficacy and safety of ...
Company to wind down the GOBLET gastrointestinal study to focus on registration path in the U.S.With sufficient cash on hand to execute near-term ...
An increasing number of people are dying of colorectal cancer at a young age. The death of actor James Van Der Beek, who was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results